Dóchas Life Sciences’ Post

Balancing Clinical and Economic Factors in Early Breast Cancer Treatment: The panelists discuss the clinical and economic factors that influence treatment decisions for early breast cancer (eBC), as well as the differences between eBC and metastatic breast cancer (mBC) in terms of adverse event management protocols and strategies for optimizing patient adherence. #finance #pharmacy #lifesciences

Key Takeaways on mBC and eBC: Key opinion leaders (KOLs) provide key takeaways on metastatic breast cancer and early breast cancer, emphasizing the enthusiasm surrounding recent advances in the field and the potential for improved patient outcomes. #finance #pharmacy #lifesciences

Highly recommended this webinar relevant for any one involved in the treatment of patients with lung cancer. Learn everything about drug-drug interactions, the pros and cons of TDM, and management of toxicity, including discussion of ESMO - European Society for Medical Oncology guidelines. You are all welcome!!

Homologous recombination deficiency (HRD) testing helps guide personalized PARP inhibitor therapy for patients living with ovarian cancer. Tune in to Labcorp Perspectives to hear from Dr. Rebecca Previs and Dr. Alison Roos on how expanded HRD testing can transform precision medicine and improve outcomes for ovarian cancer patients. Check out the latest episode to learn more about the future of precision medicine: http://spr.ly/6046YlAVe #PrecisionOncology #PersonalizedMedicine #CancerResearch #GynOnc

Very interesting comment and perspective on the I-SPY platform (https://lnkd.in/eaJSUmav). I-SPY 'clinical trials are creating a roadmap for a new clinical research vision that cuts inefficiencies, puts patients first, and defines a viable pathway for precision-based drug development. The question now is whether others will replicate the approach outside of breast cancer.' Interesting approach with a variety of applications. See Biocentury article: https://lnkd.in/em4SipbT

Optimizing Adherence to CDK4/6 Inhibitors in Metastatic Breast Cancer: Focusing on metastatic breast cancer, Aimee Keegan, PharmD, BCOP, provides clinical insights on ensuring optimal adherence to CDK4/6 inhibitors. #finance #pharmacy #lifesciences

The October issue of TPharm is now live! Considered the “Father of Tamoxifen,” for #BreastCancerAwarenessMonth, we're honoring the life of Dr. V. Craig Jordan for his significant contributions to breast cancer treatment. Hear from his colleagues and students about his dedication and leadership in the fight to treat breast cancer. Read the issue here: https://bit.ly/48bkVrN. #pharmacology

Breastcancer.org and Smart Patients are sharing this with our communities. Will you? Resources like this spark conversation and play a pivotal role in enhancing relationships between HR+/HER2- breast cancer patients and their doctors, leading to several positive outcomes: 1. Improved Understanding of Treatment Options: This provides yet another comprehensive information tool on various treatment options, including hormonal therapies and targeted treatments. This knowledge empowers patients to have more informed discussions with their healthcare providers about their treatment plan. 2. Enhanced Decision-Making: With access to detailed information about their specific type of breast cancer, patients can better understand the implications of different treatment choices for more personalized and effective decision-making in line with their preferences and lifestyle. 3. Increased Confidence and Self-Advocacy: Well-informed patients are typically more confident in their interactions with healthcare professionals. They feel more equipped to ask pertinent questions, express concerns, and advocate for their needs and preferences. 4. Better Management of Side Effects: These resources include information on managing side effects of treatments to help patients to proactively discuss side effect management strategies with their doctors, leading to improved quality of life during treatment. 5. Enhanced Adherence to Treatment Plans: When patients understand the rationale behind their treatment regimen and what to expect, they are more likely to adhere to their prescribed treatments, leading to potentially better outcomes. 6. Long-term Health Planning: Resources can guide conversations about long-term health planning, including discussions about survivorship, lifestyle modifications, and monitoring for recurrence. Combine these resources with an oncologist prescription to peer-to-peer support from Smart Patients and you have a great package to address the psychological and emotional aspects of dealing with breast cancer, offering strategies for coping and maintaining mental well-being. Between Smart Patients and Breastcancer.org (and so many more beloved breast cancer patient support networks), we can support a more holistic conversation with healthcare providers, addressing the physical and emotional challenges of the disease. (kudos to Clinical Care Options, Eli Lilly and Company and Novartis)

As shared by NCI, a meta-analysis my team and I prepared in early 2022 reviewed key data to conclude the following ➡️ Plain language summary: Immune checkpoint inhibitors (ICI), atezolizumab and pembrolizumab, have received approval for patients with triple-negative breast cancer (TNBC) expressing PD-L1. Thus far, it has only been approved for patients with unresectable locally advanced or metastatic TNBC. With the IMpassion 130 and KEYNOTE-355 trials introducing the immunotherapy era for TNBC, ongoing trials have started exploring the outcomes of the ICIs in early-stage TNBC in combination. Recently, the ICIs have demonstrated positive efficacy outcomes in neoadjuvant settings. Both the ICIs have shown a safe profile in terms of adverse events. The recent advances made by clinical trials indicate promising results for early-stage and advanced/metastatic TNBC. However, there is a need to harmonize and explore biomarkers and endpoints in the ongoing clinical trials to enhance patient treatment protocols. As TNBC is an aggressive subtype, exploring beyond the PD-L1 positive subgroup is necessary to expand the target population receiving ICIs for TNBC. Here is the full link of the study: https://lnkd.in/ejmYcqeQ While immunotherapy has taken the center stage in many clinical paradigms, my current line of work focuses on the best treatment/practices to improve AE profiles as well. #cancer #oncology #TNBC #breastcancer #research

The option to augment therapy in 1st line for EGFR mutant cancer is here, especially interesting for the large high risk groups of EGFR exon 21, brain metastases and co-mutated disease. This should be discussed as an option with all chemotherapy eligible patients. #egfr #osimertinib